Amgen
The Problem with Fast-Tracking Drug Approvals: Pharmas Fail to Follow Up
8:00PM 2/09/2011
Health Care, Genzyme Corporation , GlaxoSmithKline, Novartis, Amgen, Eli Lilly
To get potentially lifesaving drugs to patients faster, the U.S. Food and Drug Administration is allowed to approve some drugs -- those that address unmet medical needs -- based on fewer trials than usual. But it turns out that many of the pharmaceutical companies fail to conduct follow-up trials to prove the drugs work.
Amgen's Denosumab Approved for Cancer Patients
1:24PM 11/19/2010
Company News, Health Care, Novartis, Amgen, Stocks in the News
The FDA has approved Amgen's osteoporosis drug denosumab for use by cancer patients with solid tumors whose disease has metastasized to their bones. The indication to prevent complications such as fractures and bone pain among those patients could boost the drug's sales by billions.
How to Approve 'Biosimilar' Drugs? The FDA Has to Figure That Out
5:20PM 11/03/2010
Unlike generics, which are the exact chemical copies of a brand-name drug, biosimilars have large and often complex proteins that are made in living cells, and tiny differences can play havoc with the product. It may take years for the FDA to create an approval process.
Drug-makers Amgen and Johnson & Johnson are voluntarily recalling two brands of an injectable anemia medication because of the possibility that vials of it may also contain tiny glass flakes. The drug, Epoetin alfa, is marketed under the brand names Epogen and Procrit.
It's a busy time at Atlantic Media. Among President Justin Smith's initiatives are new iPad apps for The Atlantic magazine and a paid version for all Atlantic content. Plus, a total overhaul of National Journal. They're all possible because The Atlantic is set to be profitable again.
Deutsche Bank Initiates Amgen with a Hold, Dendreon with a Buy
3:36PM 8/16/2010
Company News, Investing, Health Care, Genzyme Corporation , Bristol-Myers Squibb, Amgen, Eli Lilly
Several biotech stocks were on the move Monday after Deutsche Bank started rating them. The bank's analyst, Robyn Karnauskas, took a generally wary view on the biotech sector, putting buy ratings only on Gilead and Dendreon.
Stocks in the News: BP, Ford, Toyota, AIG, Hershey, Amgen
7:54AM 6/02/2010
Company News, Investing, Earnings, Honda Motor Co, Ford Motor Co, American International Group, General Motors, Tenet Healthcare, Amgen, BP
The following is a round-up of news likely to affect stock prices today:
Shares of BP (BP) fell another 3% in London after tumbling 13% Tuesday, following news that the Obama administration was beginning a criminal probe into the Gulf of Mexico oil-drilling disaster. Investors remain skittish...
Wall Street's Health Care Relief Rally Reveals Early Winners and Losers
4:20PM 3/22/2010
Company News, Investing, Health Care, Pfizer, United Health, Merck, Tenet Healthcare, Amgen
As hyperactive and reactive as markets can be, sometimes they get it right. Witness Monday's relief rally after the House voted to overhaul health insurance. The major averages enjoyed vigorous gains, led for much of the session by, yes, the health care sector.
Amgen Says Its Drug Surpasses Rival in Preventing Fractures
1:00PM 2/09/2010
Much of the biotech's future rests on the experimental bone drug denosumab, to be sold commercially as Prolia. The drug has had its ups and downs, but Amgen says a pivotal Phase 3 clinical trial pitting denosumab against Novartis's Zometa showed that denosumab worked better.
Stocks in the News: Toyota, Electronic Arts, Coca-Cola
7:45AM 2/09/2010
The following is a round-up of news likely to affect stock prices today:
Coca-Cola (KO) reported its fourth quarter earnings climbed 55% to $1.54 billion, or 66 cents a share, on 5% higher revenue of $7.51 billion as strong volume in Latin America and other parts of the world offset a decline in...
Most Popular Stories
The Money Man Behind Rick Santorum: Who Is Foster S. Friess?
Why Your 2012 Tax Bill May Jump By $8,000
Savings Experiment: Tissues vs. Toilet Paper
Why the U.S. Should Get Rid of the $1 Bill
Savings Experiment: Snow RemovalDailyFinance Wire
- Readers' Tips for Financial Renewal, Part 4: Get the Right Job
- Tax Time for Single Parents Can Be Doubly Aggravating
- BlackBerry Loses to Apple Again
- DVDs Are Dying, and There's Worse News Ahead for Hollywood
- The Money Man Behind Rick Santorum: Who Is Foster S. Friess?
- Twice the Heart, Half the Cost: Our Readers' Budget Valentine's Day Suggestions
- Is an Amazon Store in the Real World a Good Idea?
Newswire
- Greek debt crisis eases, but drama is not over
- States, banks reach foreclosure-abuse...
- Stocks rise early after Greek deal, then...
- German minister warns on Greek austerity deal
- 2 Key leaders in Ford's renaissance will retire
- Kodak to stop making cameras, digital frames
- Pepsico to cut 8,700 jobs; 4Q net rises
- Natural gas price up on production cuts
- The $400-a-year credit card
- Fewer young adults hold jobs than ever before
- Government assistance expands
- Bob Rodriguez: The best advice I ever got
- Adventure travel bargains
- University of Charleston: How we cut tuition...
- Investing for retirement when you're just...
- Get more from a second doctor's opinion
- The Case For and Against SIRIUS XM… Value Versus Pandora? (SIRI, P)
- Mid-day Movers (IPSU, DMND, TSL, ARRY, AONE)
- Apple Captures 80% of Mobile Phone Company Profits (AAPL, SSNLF, RIMM, NOK, MMI, GOOG, MSFT)
- Meet the New Scaled Down Eastman Kodak (EKDKQ)
- After Taleo, Looking at Other Cloud M&A ‘Hopefuls’ (SKYY, TLEO, ORCL, EQIX, AKAM, RAX, TDC, NTAP, CRM)
- Morning Movers (IPSU, DMND, TLEO, IRBT, TRIP)
- Ugly Shoes Empire Expanding: Crocs Goes Into New Merchandise Territory (CROX)
- US Refined Product Imports to Increase
Follow Us
